Next-Generation Excipients Market
  • CHOOSE LICENCE TYPE
Consulting Services
    How will you benefit from our consulting services ?

Global Next-Generation Excipients Market Size, Share, Trends and Forecasts 2032

Last Updated:  Sep 10, 2026 | Study Period: 2026-2032

Key Findings

The Global Next-Generation Excipients Market is projected to reach approximately USD 8.7 Billion by 2032, up from USD 4.8 Billion in 2026, at a 10.4% CAGR.
Multifunctional and co-processed excipients account for the strongest adoption momentum as formulators seek improved flowability, compressibility, stability, and manufacturing efficiency.
Biologics, complex injectables, and advanced oral solid dosage forms are driving demand for high-purity excipients engineered for sensitive active pharmaceutical ingredients.
Rising adoption of continuous manufacturing and direct compression is compelling excipient suppliers to develop materials with tighter particle-size control and consistent functional performance.
Expansion of personalized medicine and low-dose formulations is increasing demand for excipients that enable content uniformity, solubility enhancement, and targeted release profiles.
Leading excipient manufacturers are investing in co-processing, functionalization, lipid-based delivery materials, and pharmaceutical-grade polymer platforms to strengthen product positioning globally.
Evolving regulatory expectations around excipient traceability, impurity control, and supplier qualification are shaping development and procurement priorities across the pharmaceutical industry.

Global Next-Generation Excipients Market Size and Forecast

The Global Next-Generation Excipients Market is estimated at USD 4.8 Billion in 2026 and is projected to reach USD 8.7 Billion by 2032, registering a CAGR of 10.4% during the forecast period 2026-2032. Market expansion is primarily supported by rising formulation complexity, increasing biologics and specialty-drug pipelines, and growing adoption of multifunctional excipients that improve manufacturability, solubility, stability, and drug-release performance.

Growth across co-processed excipients, functional polymers, lipid-based excipients, and high-purity specialty materials is driving demand for capabilities spanning direct compression, controlled release, solubility enhancement, and biologics stabilization. Increasing emphasis on continuous manufacturing, quality-by-design, and supplier traceability is further reshaping excipient selection and qualification strategies across the global market.

Introduction

Next-generation excipients are advanced pharmaceutical ingredients engineered beyond conventional filler, binder, lubricant, and coating functions to deliver multifunctionality, enhanced processability, improved bioavailability, controlled release, and stabilization across increasingly complex drug formulations.

The market encompasses co-processed excipients, functional polymers, lipid-based materials, high-purity sugars and polyols, solubility enhancers, and specialized excipient systems deployed across oral solids, injectables, biologics, topical products, and advanced drug-delivery platforms. Rising formulation complexity and tighter quality requirements have strengthened the strategic importance of excipient performance globally.

Future Outlook

By 2032, the Global Next-Generation Excipients Market is expected to witness sustained expansion driven by rising demand for multifunctional materials, expanding biologics and complex-drug pipelines, wider continuous-manufacturing adoption, and increasing formulation requirements for poorly soluble active ingredients worldwide.

Advances in co-processing, polymer engineering, lipid-based delivery systems, and high-purity manufacturing will define competitive differentiation. Strategic focus by excipient suppliers on regulatory documentation, application support, and co-development with pharmaceutical manufacturers will increasingly shape competitive positioning across the global market.

Application Readiness — Demand Intensity by Segment

Relative demand intensity across key segments — each bar is labelled with its demand level.

Very High High Mod–High Moderate
Very High
Oral Solid Dose Formulations
High
Biologics and Injectables
High
Controlled-Release Drug Delivery
Mod–High
Poorly Soluble Drug Formulations
Mod–High
Continuous Manufacturing
Moderate
Topical and Transdermal Products
Moderate
Nutraceutical and Specialty Applications
 Very High  High  Moderate–High  Moderate

Regional Demand and Ecosystem Development Matrix

RegionMarket MaturityKey Demand DriverDominant ApplicationGrowth Outlook
North AmericaMatureLarge innovative pharmaceutical manufacturing base and strong adoption of specialty excipientsBiologics and Advanced Oral Solid DoseHighest ↗
EuropeMatureStrong pharmaceutical quality standards and established specialty chemical ecosystemControlled-Release and High-Purity FormulationsHigh
Asia-PacificRapidly ExpandingFast-growing generic and specialty drug production with increasing local excipient sophisticationOral Solid Dose and Injectable FormulationsHigh
Middle East & AfricaEmergingGrowing local pharmaceutical manufacturing and import substitution initiativesOral Solid Dose FormulationsModerate
Latin AmericaGrowingExpanding regional generic-drug manufacturing and modernization of formulation capabilitiesOral Solid Dose and Topical FormulationsModerate–High

Product Type and Performance Comparison Matrix

Product TypePrimary FunctionPerformance LevelValue ShareKey Growth Factor
Co-Processed Multifunctional ExcipientsDirect Compression and Manufacturing EfficiencyVery HighXXXRising direct-compression and continuous-manufacturing adoption is increasing demand for multifunctional excipient systems
Functional PolymersControlled Release, Film Coating and StabilizationVery HighXXXExpanding modified-release and complex formulation pipelines are sustaining strong demand for engineered polymers
Lipid-Based ExcipientsSolubility Enhancement and Drug DeliveryHighXXXPoorly soluble APIs and advanced delivery platforms are driving adoption of lipid-based formulation systems
High-Purity Sugars and PolyolsBiologic Stabilization and BulkingHighXXXBiologics, injectables, and lyophilized formulations require tightly controlled high-purity excipient performance
Cyclodextrins and SolubilizersBioavailability and Solubility EnhancementModerate–HighXXXIncreasing formulation of low-solubility active ingredients is supporting broader use of solubilization excipients
Specialty Surfactants and EmulsifiersDispersion, Wetting and Formulation StabilityModerate–HighXXXComplex oral, injectable, and topical formulations are expanding demand for pharmaceutical-grade surfactant systems

Next-Generation Excipients Market Trends

 
Growth of Multifunctional and Co-Processed Excipients
Pharmaceutical formulators are increasingly adopting co-processed excipients that combine flow, binding, disintegration, and compressibility functions within a single material platform. This formulation-efficiency shift is the dominant force, positioning multifunctional excipients as a defining trend shaping the global market.
 
Expansion of Excipients for Biologics and Complex Injectables
Biologic and injectable pipelines are creating demand for high-purity stabilizers, cryoprotectants, surfactants, and bulking agents with tightly controlled impurity profiles. This biologics-driven requirement is reshaping supplier capabilities across the global market.
 
Rising Adoption of Continuous Manufacturing-Compatible Materials
Drug manufacturers are seeking excipients with consistent particle size, density, flowability, and compressibility for continuous production lines. This process-integration trend improves batch consistency, positioning manufacturing-compatible excipients as an important market trend.
 
Increasing Focus on Solubility and Bioavailability Enhancement
Poorly soluble drug candidates are expanding demand for cyclodextrins, lipid systems, functional polymers, and other excipients that improve dissolution and absorption. This formulation challenge is increasing the strategic importance of performance-oriented excipient selection.
 
Growth of Clean-Label and Traceable Pharmaceutical Ingredients
Pharmaceutical companies are strengthening supplier qualification, impurity monitoring, and origin traceability for critical excipients. This quality-assurance trend is increasing demand for suppliers with robust documentation and controlled manufacturing platforms.

Market Growth Drivers

 
Rising Complexity of Pharmaceutical Formulations
Growing pipelines of poorly soluble molecules, biologics, peptides, and specialty drugs are increasing the functional requirements placed on excipients. This formulation complexity supports strong demand, positioning performance-oriented materials as the primary growth driver across the global market.
 
Expanding Biologics and Injectable Drug Production
Higher production of monoclonal antibodies, vaccines, peptides, and complex injectables is increasing demand for high-purity stabilizers and processing aids. This biologics expansion supports demand for tightly controlled pharmaceutical excipients.
 
Growth of Continuous Manufacturing and Direct Compression
Pharmaceutical manufacturers are simplifying production and improving throughput through direct compression and continuous processing. This manufacturing shift supports demand for co-processed materials with predictable functional performance.
 
Increasing Need for Solubility and Bioavailability Enhancement
A growing share of development-stage active ingredients has limited aqueous solubility, increasing reliance on advanced excipient strategies. This formulation need is expanding demand for lipid-based, polymeric, and complexing excipients.
 
Stronger Regulatory Focus on Quality and Supply Reliability
Drug manufacturers are placing greater emphasis on excipient qualification, impurity control, traceability, and dual-sourcing. This quality focus supports suppliers capable of consistent pharmaceutical-grade manufacturing and documentation.

Challenges in the Market

 
Lengthy Qualification and Reformulation Cycles
Changing an excipient in an approved or late-stage pharmaceutical formulation can require extensive compatibility, stability, and regulatory work. Managing this qualification burden is challenging, positioning switching cost as a fundamental constraint across the global market.
 
High Purity and Impurity-Control Requirements
Advanced formulations require stringent control of elemental impurities, residual solvents, microbial load, and reactive contaminants. Maintaining these specifications at scale is challenging and increases manufacturing and quality-assurance costs.
 
Regulatory Variability Across Global Markets
Excipient documentation expectations, compendial standards, and regulatory treatment differ across major pharmaceutical markets. Managing this regional complexity is challenging for suppliers seeking globally harmonized product portfolios.
 
Supply-Chain Concentration for Specialty Raw Materials
Certain functional polymers, lipids, sugars, and specialty chemicals depend on concentrated upstream supply chains. Disruptions can affect pharmaceutical production continuity, making supply resilience a significant market challenge.
 
Cost Sensitivity in High-Volume Generic Formulations
Generic-drug manufacturers frequently prioritize formulation economics and may resist premium-priced specialty excipients unless manufacturing or performance benefits are clear. Demonstrating measurable value remains a structural commercialization challenge.

Competitive Landscape and Product Positioning

Leading Key Players — Relative Market Presence
Indicative relative presence based on portfolio strength & commercial reach
 
 BASF — XXX  Ashland — XXX  Roquette — XXX  Croda — XXX  Evonik — XXX  Others — XXX
 
BASF
Ludwigshafen, Germany
ProductKollidon and Soluplus Pharmaceutical Excipient Portfolio
TechnologyFunctional Polymer and Solubility-Enhancement Platform
End-userOral Solid Dose and Specialty Drug Manufacturers
Global chemical and pharmaceutical ingredient supplier offering functional polymer and solubility-enhancement excipients for advanced oral solid dose and specialty drug formulations.
 
Ashland
Wilmington, Delaware, United States
ProductPharmaceutical Cellulosics and Specialty Polymer Portfolio
TechnologyControlled-Release and Film-Coating Polymer Platform
End-userGlobal Pharmaceutical Formulators
Global specialty materials supplier offering pharmaceutical cellulosics and specialty polymers engineered for controlled release, film coating, binding, and formulation performance.
 
Roquette
Lestrem, France
ProductPEARLITOL and Pharmaceutical Excipients Portfolio
TechnologyHigh-Purity Polyol and Direct-Compression Platform
End-userOral Solid Dose and Biopharmaceutical Manufacturers
Global plant-based ingredient manufacturer supplying high-purity polyols and directly compressible excipients for oral solid dose, biologic, and specialty pharmaceutical applications.
 
Croda
Snaith, United Kingdom
ProductHigh-Purity Pharmaceutical Lipids and Surfactants
TechnologyLipid Delivery and High-Purity Excipient Platform
End-userInjectable, Biologic and Advanced Drug Delivery Developers
Global specialty chemical supplier offering high-purity lipids, surfactants, and formulation ingredients for biologics, injectables, and advanced drug-delivery systems.
 
Evonik
Essen, Germany
ProductEUDRAGIT and Advanced Drug Delivery Excipients
TechnologyFunctional Polymer and Oral Drug Delivery Platform
End-userModified-Release and Specialty Pharmaceutical Manufacturers
Global specialty chemicals company offering functional polymer and advanced drug-delivery excipients for modified-release, solubility, and specialty pharmaceutical applications.
Also covered: DFE Pharma, JRS Pharma, Colorcon, Lubrizol, Dow, and other global pharmaceutical excipient suppliers.

Next-Generation Excipients Market Segmentation

AspectsDetails
By Product Type
  • Co-Processed Multifunctional Excipients
  • Functional Polymers
  • Lipid-Based Excipients
  • High-Purity Sugars and Polyols
By Function
  • Binding and Compression
  • Solubility Enhancement
  • Controlled Release
  • Stabilization and Protection
By Dosage Form
  • Oral Solid Dose
  • Injectables and Biologics
  • Topical and Transdermal
  • Other Specialty Dosage Forms
By End User
  • Innovator Pharmaceutical Companies
  • Generic Drug Manufacturers
  • Biopharmaceutical Companies
  • Contract Development and Manufacturing Organizations

Recent Developments

BASF continued advancing its functional polymer and solubility-enhancement excipient portfolio for complex oral drug formulations globally.
Ashland progressed its specialty pharmaceutical polymer platforms for controlled-release, film-coating, and formulation-performance applications.
Roquette expanded its pharmaceutical-grade polyol and direct-compression excipient capabilities for oral solid dose and biopharmaceutical manufacturers.
Croda continued strengthening its high-purity lipid and surfactant portfolio for biologics, injectables, and advanced delivery systems.
Evonik broadened its functional polymer and drug-delivery excipient offerings for modified-release and specialty pharmaceutical applications.

This Market Report Will Answer the Following Questions

1
What is the global next-generation excipients market size in 2026?
The global next-generation excipients market is estimated at approximately USD 4.8 Billion in 2026. Demand is primarily generated by advanced oral solid dose formulations, biologics and injectables, controlled-release systems, and solubility-enhancement applications.
2
How large will the market be by 2032?
The global next-generation excipients market is forecast to reach approximately USD 8.7 Billion by 2032, compared with about USD 4.8 Billion in 2026, representing a CAGR of approximately 10.4%. Growth is expected to be supported by wider adoption of multifunctional materials, complex drug pipelines, and continuous manufacturing.
3
What is driving growth in the market?
Major growth drivers include rising formulation complexity, expanding biologics and injectable production, continuous manufacturing, increasing solubility challenges, and stronger quality requirements.
4
What are the major technology trends in the market?
The principal trends include multifunctional co-processed excipients, biologics-grade high-purity materials, continuous-manufacturing compatibility, solubility enhancement, and stronger traceability.
5
Who are the leading companies in the next-generation excipients market?
Leading suppliers include BASF, Ashland, Roquette, Croda, Evonik, DFE Pharma, JRS Pharma, and other global excipient manufacturers.

Sr NoTopic
1Market Segmentation
2Scope of the report
3Research Methodology
4Executive summary
5Key Predictions of Next-Generation Excipients Market
6Avg B2B price of Next-Generation Excipients Market
7Major Drivers For Next-Generation Excipients Market
8Global Next-Generation Excipients Market Production Footprint - 2025
9Technology Developments In Next-Generation Excipients Market
10New Product Development In Next-Generation Excipients Market
11Research focuses on new Next-Generation Excipients
12Key Trends in the Next-Generation Excipients Market
13Major changes expected in Next-Generation Excipients Market
14Incentives by the government for Next-Generation Excipients Market
15Private investments and their impact on Next-Generation Excipients Market
16Market Size, Dynamics, And Forecast, By Type, 2026-2032
17Market Size, Dynamics And Forecast, By Output, 2026-2032
18Market Size, Dynamics, And Forecast, By End User, 2026-2032
19Competitive Landscape Of Next-Generation Excipients Market
20Mergers and Acquisitions
21Competitive Landscape
22Growth strategy of leading players
23Market share of vendors, 2025
24Company Profiles
25Unmet needs and opportunities for new suppliers
26Conclusion  

Consulting Services
    How will you benefit from our consulting services ?